Literature DB >> 33536573

A new tool for technical standardization of the Ki67 immunohistochemical assay.

Thazin Nwe Aung1, Balazs Acs2,3, Jonathan Warrell4, Yalai Bai1, Patricia Gaule1, Sandra Martinez-Morilla1, Ioannis Vathiotis1, Saba Shafi1, Myrto Moutafi1, Mark Gerstein4, Benjamin Freiberg5, Regan Fulton6, David L Rimm7.   

Abstract

Ki67, a nuclear proliferation-related protein, is heavily used in anatomic pathology but has not become a companion diagnostic or a standard-of-care biomarker due to analytic variability in both assay protocols and interpretation. The International Ki67 Working Group in breast cancer has published and has ongoing efforts in the standardization of the interpretation of Ki67, but they have not yet assessed technical issues of assay production representing multiple sources of variation, including antibody clones, antibody formats, staining platforms, and operators. The goal of this work is to address these issues with a new standardization tool. We have developed a cell line microarray system in which mixes of human Karpas 299 or Jurkat cells (Ki67+) with Sf9 (Spodoptera frugiperda) (Ki67-) cells are present in incremental standardized ratios. To validate the tool, six different antibodies, including both ready-to-use and concentrate formats from six vendors, were used to measure Ki67 proliferation indices using IHC protocols for manual (bench-top) and automated platforms. The assays were performed by three different laboratories at Yale and analyzed using two image analysis software packages, including QuPath and Visiopharm. Results showed statistically significant differences in Ki67 reactivity between each antibody clone. However, subsets of Ki67 assays using three clones performed in three different labs show no significant differences. This work shows the need for analytic standardization of the Ki67 assay and provides a new tool to do so. We show here how a cell line standardization system can be used to normalize the staining variability in proliferation indices between different antibody clones in a triple negative breast cancer cohort. We believe that this cell line standardization array has the potential to improve reproducibility among Ki67 assays and laboratories, which is critical for establishing Ki67 as a standard-of-care assay.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33536573      PMCID: PMC8222064          DOI: 10.1038/s41379-021-00745-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  2 in total

1.  Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Authors:  Qi-Xing Tan; Qing-Hong Qin; Wei-Ping Yang; Qin-Guo Mo; Chang-Yuan Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.

Authors:  W Domagala; M Markiewski; B Harezga; A Dukowicz; M Osborn
Journal:  Clin Cancer Res       Date:  1996-01       Impact factor: 12.531

  2 in total
  4 in total

1.  Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.

Authors:  Guannan Wang; Alok Kumar; Wanjun Ding; Preethi Korangath; Tapan Bera; Junxia Wei; Priya Pai; Kathleen Gabrielson; Ira Pastan; Saraswati Sukumar
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-08       Impact factor: 12.779

2.  Optimal settings and clinical validation for automated Ki67 calculation in neuroendocrine tumors with open source informatics (QuPath).

Authors:  Rima Pai; Susan Karki; Rakhee Agarwal; Steven Sieber; Samuel Barasch
Journal:  J Pathol Inform       Date:  2022-09-21

3.  Integrating morphologic and molecular histopathological features through whole slide image registration and deep learning.

Authors:  Kevin Faust; Michael K Lee; Anglin Dent; Clare Fiala; Alessia Portante; Madhumitha Rabindranath; Noor Alsafwani; Andrew Gao; Ugljesa Djuric; Phedias Diamandis
Journal:  Neurooncol Adv       Date:  2022-01-05

4.  Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.

Authors:  Balazs Acs; Samuel C Y Leung; Kelley M Kidwell; Indu Arun; Renaldas Augulis; Sunil S Badve; Yalai Bai; Anita L Bane; John M S Bartlett; Jane Bayani; Gilbert Bigras; Annika Blank; Henk Buikema; Martin C Chang; Robin L Dietz; Andrew Dodson; Susan Fineberg; Cornelia M Focke; Dongxia Gao; Allen M Gown; Carolina Gutierrez; Johan Hartman; Zuzana Kos; Anne-Vibeke Lænkholm; Arvydas Laurinavicius; Richard M Levenson; Rustin Mahboubi-Ardakani; Mauro G Mastropasqua; Sharon Nofech-Mozes; C Kent Osborne; Frédérique M Penault-Llorca; Tammy Piper; Mary Anne Quintayo; Tilman T Rau; Stefan Reinhard; Stephanie Robertson; Roberto Salgado; Tomoharu Sugie; Bert van der Vegt; Giuseppe Viale; Lila A Zabaglo; Daniel F Hayes; Mitch Dowsett; Torsten O Nielsen; David L Rimm
Journal:  Mod Pathol       Date:  2022-06-21       Impact factor: 8.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.